Effect of oxelidine on analgesic efficacy and postoperative adverse reactions after thermal ablation of hepatocellular carcinoma: a prospective, double-blind, randomized controlled study

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400093853

Enrollment

Unknown

Registered

2024-12-12

Start date

2024-12-15

Completion date

Unknown

Last updated

2024-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver cancer

Interventions

Oliceridine Group:The patient was given a single intravenous infusion of oxelidine 1.5mg 10 minutes before the end of the operation

Dezocin Group:The patient was given a single intravenous injection of dezocine 5mg 10 minutes before the end of the operation

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) ASA I~? grade; 2) Hepatocellular Carcinoma (HCC) is diagnosed with tumor diameter less than 3 cm; The number of tumors does not exceed 3; 3) Liver function Child A-B; 4) Non-pregnant, nursing patients, etc.; 5) Agree to sign the informed consent form

Exclusion criteria

Exclusion criteria: 1) Complicated with serious heart, brain, lung, kidney and other organ dysfunction; 2) Allergic to the investigational drug; 3) Mental patients; 4) Opioid abuse; 5) cannot match NRS score;

Design outcomes

Primary

Measure	Time frame
NRS 2 hours after surgery;	—

Secondary

Measure	Time frame
Ramsay sceal;Use of additional postoperative analgesics;PONV severity score;Satisfaction with analgesic effect;Alanine aminotransferase;Aspartate transaminase;Total bilirubin;Albumin level;	—

Countries

China

Contacts

Public ContactXiong Erfeng

The Third Affiliated Hospital of Sun Yat-sen University

xiongerf@mail.sysu.edu.cn+86 188 9959 4966

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026